Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.51 |
| ▸ | MDM4 | O15151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094886 | 1.00 | MDM2 (0.51) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL16094888 | 1.00 | MDM2 (0.51) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL30241225 | 1.00 | MDM2 (0.51) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL16095683 | 0.92 | MDM2 (0.51) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL30191462 | 0.92 | MDM2 (0.51) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL30005445 | 0.92 | MDM2 (0.51) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL16095681 | 0.92 | MDM2 (0.51) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL26980958 | 0.91 | PTPN1 (0.47) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL26980967 | 0.91 | PTPN1 (0.47) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL3728822 | 0.91 | MDM2 (0.54) | MDM2MDM4TP53PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | BICYCLETX LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | MDM2 737/4885MDM4 2209/4885TP53 300/4885 |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | TSLP, VIP, CCL2 | MDM2 737/4885MDM4 2209/4885TP53 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.